The longer you wait to take a missed dose, the faster your metabolic advantage erodes
N Engl J Med 373(23):22472257 Muskiet MHA, Tonneijck L, Huang Y, Liu M, Saremi A, Heerspink HJL et al (2018) Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial
3.8/5 stars 117 reviews More balanced view - acknowledges some positive experiences but recurring delivery/service issues
Continuous variables are presented as mean standard deviation while non-normally distributed variables as median and interquartile ranges
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists (updated meta-analysis) Sattar N et al